ATI-502 is a topical Janus Kinase (JAK) 1/3 inhibitor.
The approval was supported by Phase 3 data from the ATMOS-1 and ATMOS-2 trials which evaluated the absolute change from baseline in sweat production after treatment with Qbrexza, and the proportion of patients who achieved ≥4-point improvement from baseline in their sweating severity (as measured by the Axillary Sweating Daily Diary [ASDD]).
Scenesse (Clinuvel Pharmaceuticals) is a bimonthly, subcutaneous dose of afamelanotide 16mg.
CVS Pharmacy is now offering home delivery nationwide for prescription drugs, for a service charge of $4.99.
Informed consent, privacy, and justice concerns are 3 issues that should be addressed before the use of online genealogy data in criminal cases becomes widely adopted.
Between October 20, 2017 and February 20, 2018, the Vaccine Adverse Event Reporting System (VAERS) received 155 reports involving RZV, with 13 (8%) involving an administrative error.
The approval was based on a multicenter, randomized, evaluator-blinded, split-hand study (N=89) which showed that treatment with Restylane Lyft resulted in a clinically meaningful improvement in the correction of volume deficits of treated hands for up to 6 months.
The approval was based on data from a randomized, placebo-controlled trial that included 149 adults with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a static Physician Global Assessment (sPGA) score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for the treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.